One-glance verdict
Overvalued
$74.78 our estimate vs market $145.73
Wall Street consensus: $126.12 (68.7% higher than our fair-value estimate)
95% above our estimate, beyond the bull case
Fundamentals snapshot
Revvity, Inc.
RVTY · NYQ · Healthcare · Diagnostics & Research
Current price
$145.73
52-week range
$81.22 - $147.50
Market cap
$16.26B
Balance sheet
Stretched
3.87x Stretched
Net debt $2.32B. Interest coverage shows how many times profit covers the interest bill.
What stands out
3 Rewards
3 Risks
3 rewards · 3 risks
- Reward Revenue grew 2.0% last year.
- Reward Returns 3.2% on equity, ahead of 50% of its peers.
- Risk Stock trades 89.6% above its 5-year average P/E.
- Risk Operating margin compressed from 22.4% to 17.1% over 3 years.
What this company does
Revvity, Inc.
Revvity sells the specialized lab equipment and supplies that scientists use to develop new drugs and that doctors use to screen for diseases. The company makes a lot of its money not just from selling the initial machines, but from the continuous sales of necessary testing supplies, which creates reliable recurring revenue (income the company can regularly count on). This makes Revvity an essential supplier for drug companies and healthcare labs working on everything from cancer research to newborn health tests.
How the company got here
Revvity started as a long-standing company called PerkinElmer, which was founded in 1937. For many years, PerkinElmer was involved in several different businesses. In 2023, the company made a big change by selling off its divisions related to food safety and environmental testing, deciding to focus purely on healthcare. The remaining, more focused company was renamed Revvity, a name created by combining the words 'revolutionize' and 'vita,' the Latin word for life, to signal its new direction.
What it actually does
Revvity provides the tools, technologies, and services that scientists and doctors use to research diseases and diagnose patients. Think of it as selling the high-tech 'shovels and pickaxes' for the health science gold rush. Their customers, like pharmaceutical companies, research universities, and medical labs, buy Revvity's instruments, software, and consumable supplies (like chemicals called reagents, which are used to conduct experiments or tests) to discover new drugs and test for diseases.
Life Sciences
This is Revvity's largest business, making up a little more than half of its sales. It provides the essential tools for scientists who are in the early stages of discovering and developing new medicines. Customers at drug companies, biotech firms, and universities buy Revvity's automated lab equipment, imaging systems, and specialized software to speed up their research. This part of the company helps researchers understand diseases at a microscopic level, aiming to find new ways to treat them.
Diagnostics
This part of the company focuses on tools that help doctors and labs diagnose health conditions. A major area for them is newborn screening, where they provide tests to check babies for rare but serious conditions right after birth. They also make equipment and tests for reproductive health and for identifying infectious and autoimmune diseases (where the body's immune system attacks its own tissues). This segment sells complete testing systems—the machine, the chemical kits, and the software—to hospitals and private labs.
What management is betting on now
After slimming down the company, management's main goal is to be a more focused and faster-growing leader in its two core areas. They are investing in creating complete, end-to-end workflows (systems where their instruments, software, and chemical supplies all work together seamlessly) to make their customers' jobs easier and keep them loyal. The company is also focused on expanding its menu of available diagnostic tests and making small, strategic acquisitions (buying smaller companies) to add new technologies.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$149.78M
FY2025 Q1
$112.17M
FY2025 Q2
$115.45M
FY2025 Q3
$120.00M
FY2025 Q4
$161.79M
FY2026 Q2
$95.45M
FY2026 Q3
$180.87M
Revenue
$729.69M
Net income
$51.82M
Diluted EPS
0.47
Operating cash flow
$191.94M
Free cash flow
$180.87M
Fetching…
Sources
Revenue
$711.12M
Net income
$40.72M
Diluted EPS
0.36
Operating cash flow
$115.23M
Free cash flow
$95.45M
Fetching…
Sources
Revenue
$772.06M
Net income
$98.36M
Diluted EPS
0.86
Operating cash flow
$181.96M
Free cash flow
$161.79M
Fetching…
Sources
Revenue
$698.95M
Net income
$46.65M
Diluted EPS
0.40
Operating cash flow
$138.50M
Free cash flow
$120.00M
Fetching…
Sources
Revenue
$720.28M
Net income
$53.95M
Diluted EPS
0.46
Operating cash flow
$134.32M
Free cash flow
$115.45M
Fetching…
Sources
Revenue
$664.76M
Net income
$42.24M
Diluted EPS
0.35
Operating cash flow
$128.16M
Free cash flow
$112.17M
Fetching…
Sources
Revenue
$729.37M
Net income
$94.64M
Diluted EPS
0.77
Operating cash flow
$174.23M
Free cash flow
$149.78M
Fetching…
Sources
Is it cheap or expensive?
Fair value $74.78 vs current price $145.73
Wall Street consensus is the average analyst price target: $126.12 (68.7% higher than our fair-value estimate).
Our most-likely fair value is $74.78 a share — about 48.7% below today's price of $145.73, so the stock currently looks expensive (overvalued).
Is it drowning in debt?
Stretched
Net debt $2.3B. Interest coverage 3.9x.
Net debt
$2.32B
Interest coverage
3.87x
Revvity, Inc.'s profit covers its interest bill about 3.9 times over. which is weaker than most peers shown here.
Stretched
Worse cushion
Baseline
Better cushion
RVTY
BASELINE
Revvity, Inc.
Total debt $3.34B Interest coverage 3.87x This is the baseline the peer rows are being compared against.
Total debt $289.09M Interest coverage 28.31x +632% vs RVTY Carries about 7.3x more debt cushion than RVTY.
Total debt $1.86B Interest coverage 3.91x +1% vs RVTY Has roughly the same debt cushion as RVTY.
Total debt $1.37B Interest coverage 4.46x +15% vs RVTY Carries about 1.2x more debt cushion than RVTY.
Total debt $1.65B Interest coverage 15.65x +304% vs RVTY Carries about 4.0x more debt cushion than RVTY.
Total debt $5.48B Interest coverage 11.54x +198% vs RVTY Carries about 3.0x more debt cushion than RVTY.
What you should know
The case for and against RVTY
3 Rewards
3 Risks
Rewards
-
Revenue grew 2.0% last year.
-
Returns 3.2% on equity, ahead of 50% of its peers.
-
Free cash flow was positive in 10/10 years.
Risks
-
Stock trades 89.6% above its 5-year average P/E.
-
Operating margin compressed from 22.4% to 17.1% over 3 years.
-
Insider ownership is only 0.3% (peer median: 0.5%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
70.06x
Forward P/E
24.73x
P/B
2.25x
P/S
5.58x
EV/EBITDA
21.21x
PEG ratio
0.73x
Profitability
How much profit each dollar creates
Gross margin
55.0%
Operating margin
17.1%
Net margin
8.2%
ROE
3.2%
ROA
2.4%
Health
Liquidity and balance-sheet strength
Debt / equity
0.46x
Current ratio
1.80x
Quick ratio
1.36x
Total debt
$3.34B
Total cash
$1.02B
Growth
How the business has been compounding
Revenue TTM
$2.91B
Revenue 5Y CAGR
-13.4%
EPS TTM
2.08
EPS 5Y CAGR
-23.3%
Cash flow
How much cash the business throws off
Operating CF TTM
$627.63M
Free CF TTM
$509.41M
FCF margin
17.5%
Dividend
Shareholder payout
Yield
0.2%
Payout ratio
13.5%
Last ex-div date
2026-10-23